InterCure Ltd. (TLV:INCR)
Israel · Delayed Price · Currency is ILS · Price in ILA 269.80
-6.40 (-2.32%)
Jun 19, 2026, 1:44 PM IDT
InterCure Employees
InterCure had 285 employees as of December 31, 2025. The number of employees decreased by 35 or -10.94% compared to the previous year.
Employees
285
Change (1Y)
-35
Growth (1Y)
-10.94%
Revenue / Employee
948.07K ILS
Profits / Employee
-125.30K ILS
Market Cap
147.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 285 | -35 | -10.94% |
| Dec 31, 2024 | 320 | 50 | 18.52% |
| Dec 31, 2023 | 270 | -100 | -27.03% |
| Dec 31, 2022 | 370 | 20 | 5.71% |
| Dec 31, 2021 | 350 | 275 | 366.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 32,842 |
| Kamada | 462 |
| Rekah Pharmaceutical Industry | 390 |
| Together Pharma | 210 |
| Seach Medical Group | 162 |
| Tikun Olam-Cannbit Pharmaceuticals | 4 |
InterCure News
- 5 days ago - InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition - GlobeNewsWire
- 7 weeks ago - InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow - GlobeNewsWire
- 3 months ago - InterCure receives noncompliance notification from Nasdaq - TheFly
- 3 months ago - InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement - GlobeNewsWire
- 4 months ago - InterCure reports preliminary FY25 revenue NIS 265M - TheFly
- 4 months ago - InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million - GlobeNewsWire
- 8 months ago - InterCure, Cannasoul sign strategic investment, collaboration agreements - TheFly
- 8 months ago - InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation - GlobeNewsWire